Research progress on differential improvement and mechanism of nucleoside analogues or nucleotide analogues in HBV-related hepato-cellular carcinoma
10.12092/j.issn.1009-2501.2025.06.014
- VernacularTitle:核苷与核苷酸类抗病毒药物对乙型肝炎相关肝细胞癌的差异性改善及其机制
- Author:
Menghan JIN
1
;
Suwen JIANG
;
Airong HU
;
Ken LIN
;
Ying FAN
;
Jialan WANG
;
Haojin ZHANG
Author Information
1. 宁波大学医学部,宁波 315211,浙江
- Publication Type:Journal Article
- Keywords:
hepatitis B virus;
hepatocellular carci-noma;
nucleoside analogues;
nucleotide ana-logues;
differentiation
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2025;30(6):835-848
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus(HBV)infection is the main risk factor for the development and progres-sion of hepatocellular carcinoma(HCC).Through re-peated inflammatory stimulation,liver cells regen-eration,fibrosis,and scar formation,it may eventu-ally progress to HCC.Antiviral treatment reduces the incidence of HBV-related HCC and the risk of postoperative recurrence by reducing HBV DNA lev-el,thereby improving prognosis.Many recent stud-ies have found that different kinds of nucleos(t)ide analogues(NAs)may have differential improve-ments in the prevention of HBV-related HCC occur-rence and postoperative recurrence.This article re-views the differential improvement of different cat-egories of NAs in HBV-related HCC and the possible mechanisms.
